The Value of Colloidal Silver in the Treatment of COVID-19
试验速览
- 阶段
- 不适用
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Chage of clinical status
研究概览
简要总结
Noble metals such as gold and silver have been appreciated for millennia not only for their beauty but also for their ability to fight diseases.
Silver nanoparticles (AgNPs) have been employed as chemical drugs thanks to their unique physiochemical and chemical properties as well as biological features, such as anti-inflammatory, anti-angiogenesis, antiplatelet, antifungal, anti-cancer and antibacterial activities I
详细描述
Noble metals such as gold and silver have been appreciated for millennia not only for their beauty but also for their ability to fight diseases.
Silver nanoparticles (AgNPs) have been employed as chemical drugs thanks to their unique physiochemical and chemical properties as well as biological features, such as anti-inflammatory, anti-angiogenesis, antiplatelet, antifungal, anti-cancer and antibacterial activities Infectious diseases account for more than 20% of global mortality and viruses are responsible for about one-third of these deaths. Highly infectious viral diseases such as severe acute respiratory (SARS), Middle East respiratory syndrome (MERS) and coronavirus disease (COVID-19) are emerging more frequently and their worldwide spread poses a serious threat to human health and the global economy.
The current COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Inclusion of any patient, over the age of 18, consulting the Sahloul emergencies, Sousse for symptoms of COVID -19 dating less than 10 days and having a positive COVID-19 on the PCR test and typical scanner.
排除标准
- •Any pregnant or breastfeeding woman
- •patient with an expectation of survival of less than 24 hours
- •Dyspnea leading to heart failure
- •Hepatic insufficiency
- •Chronic respiratory failure
- •Renal failure, clearance <20ml • min-1 • 1.73 • m-²
研究组 & 干预措施
Silver Group
- Orally: the colloidal agent 1 dose of 30ml, 3 times a day for 5 days (use a plastic measuring cup and not a measuring cup or a metal spoon)
- By inhalation: nebulization of 5ml of colloidal silver solution once, 3 times a day for 5 days.
干预措施: Colloidal Silver (Drug)
Placebo Group
- Orally: EPPI 1 dose of 30 ml, 3 times a day for 5 days
- By inhalation: nebulization of 5ml of EPPI solution once a day, 3 times a day for 5 days.
干预措施: Placebo (Drug)
结局指标
主要结局
Chage of clinical status
时间窗: 10 DAYS
the distribution of clinical status assessed on the 7-point ordinal scale on day 10 of the study
次要结局
- Adverse events(ON 1 month)
- the duration of the different respiratory assistance modes(ON 11 days)
- the duration of hospitalization(ON 11 days)
- all-cause mortality(ON 1 month)
研究者
Riadh Boukef
PROFESSOR
Hôpital Universitaire Sahloul